Press Releases

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics
5 November 2013 LAUSANNE, SWITZERLAND and SOUTH SAN FRANCISCO, CA, USA – November 5 2013 − ADC Therapeutics Sàrl (‘ADC Therapeutics’), a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), and Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and

AstraZeneca’s MedImmune Acquires Spirogen, Invests in ADC Therapeutics

AstraZeneca’s MedImmune Acquires Spirogen, Invests in ADC Therapeutics
15 October 2013 Auven Therapeutics Announces AstraZeneca’s MedImmune Acquires Antibody-Drug Conjugate Company Spirogen and Invests in ADC Therapeutics Both Auven Therapeutics Portfolio Companies MedImmune acquires 100% of Spirogen for $200 million in cash and deferred consideration of up to $240 million MedImmune and ADC Therapeutics enter into a collaboration agreement for two of ADC Therapeutics’

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer
15 July 2013 Lausanne, Switzerland and New York, US – 15 July 2013 − ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead
16 June 2013 Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax®-TAC with next generation PBD-based warhead technology 50:50 partnership Copenhagen, Denmark and Lausanne, Switzerland; 17 June 2013 – Genmab A/S (OMX: GEN) and ADC Therapeutics, announced today an agreement to develop a new antibody-drug conjugate (ADC) product combining Genmab’s HuMax-TAC antibody